酸脱酶激酶抑制剂的最新进展:结构,抑制机制和生物活动
Yiyang Li1, Zhizhong Xie1, Xiaoyong Lei1
1Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.
向酸盐脱酶激酶 (PDKs) 抑制癌细胞代谢,促进细胞亡. 本综述总结了PDKs抑制剂,它们的结合部位,以及癌症治疗的临床潜力.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 癌细胞表现出代谢重编程,有利于能量和前体合成的糖解.
- 酸盐脱酶激酶 (PDKs) 在癌症中被上调,抑制酸盐脱酶复合体 (PDC) 并促进糖解.
研究的目的:
- 审查癌症治疗PDKs抑制剂的最新进展.
- 根据其结合位点对PDKs抑制剂进行分类,并分析其结构特征.
- 探索PDKs抑制剂的临床应用价值和未来方向.
主要方法:
- 关于PDKs抑制剂的最近研究的文献综述.
- 基于其与不同PDKs结合部位的相互作用的抑制剂的分类.
- 对已识别的抑制剂的结构特征和临床进展进行分析.
主要成果:
- PDKs 抑制剂有效地阻断了癌细胞对糖解的代谢过渡.
- 抑制PDKs会重新激活线粒体的氧化代谢,并诱导癌细胞的亡.
- 新的PDKs抑制器结构正在不断被发现,其中一些进展到临床试验.
结论:
- PDKs 抑制剂通过向癌细胞代谢,代表了一个有前途的治疗策略.
- 了解抑制剂结合部位对于设计有效和特定药物至关重要.
- 需要进一步的研究来克服局限性并优化PDKs抑制剂的临床使用.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
相关概念视频
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Inhibition of Cdk Activity
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Enzyme Inhibition
Pyruvate Oxidation
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...
